MALARONE PEDIATRIC Rx
Generic Name and Formulations:
Atovaquone 62.5mg, proguanil HCl 25mg; tabs.
Indications for MALARONE PEDIATRIC:
Prophylaxis of P. falciparum malaria (including chloroquine-resistant strains). Treatment of acute uncomplicated P. falciparum malaria.
Adults and Children:
Take at the same time each day with food or a milky drink. Children: may crush and mix with condensed milk if unable to swallow tabs. Repeat dose if vomiting occurs within 1 hour. Prophylaxis (once daily starting 1–2 days before entering endemic area, during stay, and for 7 days after return): <11kg: not recommended (see Treatment); 11–20kg: 62.5mg atovaquone/25mg proguanil; 21–30kg: 125mg/50mg; 31–40kg: 187.5mg/75mg. >40kg: 250mg/100mg. Treatment (give as single daily dose for 3 consecutive days): <5kg: not recommended; 5–8kg: 125mg/50mg; 9–10kg: 187.5mg/75mg; 11–20kg: 250mg/100mg; 21–30kg: 500mg/200mg; 31–40kg: 750mg/300mg. >40kg: 1g/400mg.
Prophylaxis in severe renal impairment (CrCl <30mL/min).
Use other therapy in severe malaria, recrudescence, or prophylaxis failure. Monitor parasitemia closely and consider other therapy in severe or persistent diarrhea or vomiting (may use antiemetics). Hepatic or renal impairment (CrCl <30mL/min): consider alternate therapy for treatment. Elderly. Pregnancy (Cat.C; may continue folate supplements). Nursing mothers.
Concomitant rifampin, rifabutin: not recommended. Atovaquone antagonized by tetracycline, metoclopramide. Proguanil may potentiate warfarin or other coumarin-based anticoagulants (monitor). Caution with indinavir, CYP2C19 substrates or inhibitors.
Naphthoquinone + dihydrofolate reductase inhibitor.
GI upset/pain, headache, asthenia, anorexia, dizziness, elevated liver function tests; rare: anaphylaxis, vasculitis, hepatitis, cholestasis. Children: vomiting, pruritus.
Tabs—24, 100; Ped tabs—100
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies